AstraZeneca plc (AZN) Earns Hold Rating from Shore Capital
Shore Capital reaffirmed their hold rating on shares of AstraZeneca plc (LON:AZN) in a research report sent to investors on Monday morning, Marketbeat.com reports.
A number of other research analysts also recently commented on AZN. Liberum Capital reaffirmed a buy rating and set a GBX 5,500 ($72.31) target price on shares of AstraZeneca plc in a report on Wednesday, June 14th. Jefferies Group LLC increased their target price on AstraZeneca plc from GBX 5,000 ($65.74) to GBX 5,500 ($72.31) and gave the stock a hold rating in a report on Friday, June 16th. Deutsche Bank AG reaffirmed a buy rating and set a GBX 5,700 ($74.94) target price on shares of AstraZeneca plc in a report on Friday, June 16th. Credit Suisse Group reaffirmed a neutral rating and set a GBX 5,000 ($65.74) target price on shares of AstraZeneca plc in a report on Monday, June 19th. Finally, Morgan Stanley reaffirmed an overweight rating and set a GBX 5,600 ($73.63) target price on shares of AstraZeneca plc in a report on Friday, June 23rd. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company’s stock. AstraZeneca plc has a consensus rating of Hold and a consensus price target of GBX 5,113.55 ($67.23).
Shares of AstraZeneca plc (LON AZN) opened at 5148.00 on Monday. The stock’s 50 day moving average price is GBX 4,796.35 and its 200 day moving average price is GBX 4,903.40. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00. The firm’s market cap is GBX 65.17 billion.
In other news, insider Nazneen Rahman purchased 39 shares of the stock in a transaction dated Thursday, July 27th. The shares were bought at an average cost of GBX 4,370 ($57.45) per share, for a total transaction of £1,704.30 ($2,240.73).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.